NSAID-induced nephrotoxicity from the fetus to the child

Drug Safety

Volumn 24, Issue 1, 2001, Pages 9-18

  Cuzzolin, L ^a   Dal Cere M ^a   Fanos, V ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOROLAC; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PROSTANOID RECEPTOR ANTAGONIST; SULINDAC; UNCLASSIFIED DRUG;

ANALGESIA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; FETOTOXICITY; FETUS; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; KIDNEY FAILURE; META ANALYSIS; NEPHROTOXICITY; PATENT DUCTUS ARTERIOSUS; PRENATAL EXPOSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0035147290     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200124010-00002     Document Type: Review

References (98)

1. NSAIDs and their effect on renal function
2. Drug-induced renal disease
3. Renal syndromes associated with nonsteroidal anti-inflammatory drugs
4. Adverse effects of nonsteroidal anti-inflammatory drugs on renal function
5. Grand round: Nephrotoxicity of non-steroidal anti-inflammatory drugs
6. Renal complications of non-steroidal drugs
7. The renal effects of nonsteroidal anti-inflammatory drugs. Summary and recommendations
8. Prostanoid biosynthesis and mechanism of action
9. Prostanoid receptors: Structures, properties and functions
10. Renal complications associated with the use of nonsteroidal anti-inflammatory agents
11. Renal failure in the neonate associated with in utero exposure to non-steroidal anti-inflammatory agents
12. COX-1 and COX-2 tissue expression: Implications and predictions
13. Cloning, expression and regulation of rabbit cyclo-oxygenase-2 in renal medullary interstitial cells
14. Localization of cyclo-oxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function
15. Expression of cyclo-oxygenase types- 1 and -2 in human fetal membranes throughout pregnancy
16. Use of a cyclo-oxygenase type-2-selective non-steroidal anti-inflammatory agent to prevent preterm delivery
17. Expression of cyclo-oxygenases in ductus arteriosus of fetal and newborn pigs
18. Permanent anatomic closure of the ductus arteriosus in newborn baboons: The roles of postnatal constriction, hypoxia and gestation
19. Cyctooxygenase-2 plays a significant role in regulating the tone of the fetal lamb ductus arteriosus
20. Prostaglandin receptors: Their role in regulating renal function
21. Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes
22. Roles of prostaglandin E receptors in mesangial cells under high-glucose conditions
23. Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype
24. International union of pharmacology classification of prostanoid receptors: Properties, distribution and structure of the receptors and their subtypes
25. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice
26. Renal action of prostacyctin
27. Stimulation of renin release by PGE2 and PGI2 infusion in the dog: Enhancing effect of ureteral occlusion or administration of ethacrynic acid
28. Characterization of glomerular thromboxane receptor sites in the rat
29. Indomethacin in the treatment of premature labor
30. Maternal indomethacin therapy in the treatment of polyhydramnios
31. Effect of advancing gestational age on the frequency of fetal ductal constriction in association with maternal indomethacin use
32. Prostaglandins and the developing kidney
33. Fetal and neonatal effects of indomethacin used as a tocolytic agent
34. Neonatal outcome after indomethacin treatment for preterm labor
35. Efficacy and safety of indomethacin versus ritodine in the management of preterm labor: A randomized study
36. Prenatal administration of indomethacin as a tocolytic agent: Effect on neonatal renal function
37. Oligohydramnios, meconium and perinatal death concurrent with indomethacin treatment in human pregnancy
38. Effets maternels et néonatals de l'indomethacine administrëe pendant la grossesse
39. Neonatal complications after the administration of indomethacin for preterm labor
40. The effect of indomethacin tocolysis in preterm labour on perinatal outcome: A randomized placebo-controlled trial
41. Acute renal failure in the neonate induced by the administration of indomethacin as a tocolytic agent
42. Renal dysgenesis in a monozygotic twin: Association with in utero exposure to indomethacin
43. Neonatal renal dysfunction and intrauterine exposure to prostaglandin synthesis inhibitors
44. Antenatal indomethacin - Adverse fetal effects confirmed
45. Persistent anuria, neonatal death and renal microcystic lesions after prenatal exposure to indomethacin
46. Indomethacin and the fetal renal non function syndrome
47. Medical treatment of patent ductus arteriosus in premature infants
48. Randomized trial of early closure of symptomatic patent ductus arteriosus
49. Closure of the ductus arteriosus with indomethacin in ventilated neonates with respiratory distress syndrome: Effects on pulmonary compliance and ventilation
50. Treatment of patent ductus arteriosus with ibuprofen
51. Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infants
52. Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus
53. Treatment of patent ductus arteriosus with low-dose indomethacin in very low birth weight neonates with impairment of renal function: Report of three cases
54. Renal effects and urinary excretion of prostaglandin following indomethacin therapy in premature infants with patent ductus arteriosus
55. Low dose indomethacin and prevention of intraventricutar hemorrhage: A multicenter randomized trial
56. Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus
57. Comparing sulindac with indomethacin for closure of ductus arteriosus in preterm infants
58. Ibuprofen treatment of patent ductus arteriosus
59. Early administration of indomethacin to preterm infants
60. Indomethacin-induced changes in renal blood flow velocity waveform in premature infants investigated with color Doppler imaging
61. Aspirin versus indomethacin treatment of patent ductus arteriosus in preterm infants with respiratory distress syndrome
62. Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants
63. Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus: A double-blind controlled study
64. Early closure of the patent ductus arteriosus in very low birth weight infants: A controlled trial
65. Effects of indomethacin in premature infants with patent ductus arteriosus: Results of a national collaborative study
66. Prophylactic indomethacin therapy for patent ductus arteriosus in very-low-birth-weight infants
67. Symptomatic patent ductus arteriosus following prophylactic indomethacin
68. Prevention of symptomatic patent ductus arteriosus with a single dose of indomethacin
69. Effect of indomethacin on the cerebral blood flow velocity of premature newborns
70. Furosemide prevents renal side-effects of indomethacin therapy in preterm infants with pesistent ductus arteriosus
71. Prolonged low dose indomethacin for persistent ductus arteriosus of prematurity
72. Prolonged indomethacin therapy for the prevention of recurrences of patent ductus arteriosus
73. Effect of dopamine on failure of indomethacin to close the patent ductus arteriosus
74. Closure of PDA with mefenamic acid
75. Therapy of symptomatic patent ductus arteriosus in preterms using mefenamic acid and indomethacin
76. Age-dependent changes in the response of the lamb ductus arteriosus to oxygen and ibuprofen
77. Prostanoids determine the range of cerebral blood flow autoregulation of newborn piglets
78. Differences in the effects in the newborn piglet of various nonsteroidal anti-inflammatory drugs on cerebral blood flow but not on cerebrovascular prostaglandins
79. Indomethacin compromises hemodynamics during positive-pressure ventilation, independently of prostanoids
80. Prevention of postasphyxial increase in lipid peroxides and retinal function deterioration in the newborn pig by inhibition of cyctooxygenase activity and free radical generation
81. The effect of early intravenous ibuprofen on renal function in premature newborns
82. Ibuprofen vs indomethacin for treatment of PDA in preterm infants
83. Acute flank pain and reversible renal dysfunction associated with nonsteroidal anti-inflammatory drug use
84. A unique complication of nonsteroidal anti-inflammatory drug use
85. Renal function after short term ibuprofen use in infants and children
86. Drug evaluation after marketing: A policy perspective
87. When a randomized controlled trial is needed to assess drug safety: The case of pediatric ibuprofen
88. Hypocalcemia and hypomagnesemia after ibuprofen overdose
89. Safety of paracetamol and ibuprofen in febrile children
90. Acute renal insufficiency in ibuprofen overdose
91. Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis
92. An assessment of the safety of pediatric ibuprofen: A practitioner-based randomized clinical trial
93. Care in the use of ibuprofen as an antipyretic in children
94. Acute nonoliguric renal failure in children associated with nonsteroidal anti-inflammatory agents
95. Ketorolac-induced irreversible renal failure in sickle cell disease: A case report
96. Reversible renal failure associated with ibuprofen in a child: A case report
97. Antibacterial-induced nephrotoxicity in the newborn
98. Mechanisms of action of anti-inflammatory drugs